Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 19, 2012

JSR Teams with BIA to Develop and Market Purification Systems

  • JSR and BIA Separations entered a partnership that includes JSR taking a minor equity position on November 14, 2011. The companies started a joint global marketing and sales effort as well as collaborative R&D activities in the area of downstream purification to aid in the manufacture of vaccines, DNA, and antibody-based medicines.

    Through this arrangement JSR gains access to BIA Separations’ downstream purification technology. BIA’s technology will be combined with JSR’s Protein A media. BIA expects JSR’s global presence and expertise in the field of consistent high-quality volume manufacturing will help it successfully grow its business.

    JSR is headquartered in Tokyo and has factories and offices in Europe, the U.S., China, Taiwan, Korea, and Singapore. BIA Separations claims to be the only worldwide developer and manufacturer of CIM Convective Interaction Media®, short monolithic chromatographic columns optimized for the separation and purification of large biomolecules and viral particles on the laboratory and industrial scale.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »